Literature DB >> 23448761

Anxiety and depression in patients with Parkinson's disease.

Toshiyuki Yamanishi1, Hisao Tachibana, Miyako Oguru, Kiyohiro Matsui, Kazuo Toda, Bungo Okuda, Nobuyuki Oka.   

Abstract

OBJECTIVE: To investigate the prevalence and clinical correlates of anxiety and depression in patients with Parkinson's disease (PD) and to examine the relationship between anxiety and depression and the quality of life (QOL).
METHODS: One hundred and seventeen patients with PD completed the state-trait anxiety inventory (STAI), the beck depression inventory second edition (BDI-II), Starkstein's apathy scale (AS) and QOL battery. Hoehn and Yahr (HY) staging, the unified Parkinson's disease rating scale (UPDRS) and the mini-mental state examination (MMSE) were administered on the same day.
RESULTS: Anxiety (STAI score ≥41 for men or ≥42 for women) was diagnosed in 55% of the patients and depression (BDI-II score ≥14) was diagnosed in 56% of the patients. Anxiety coexisted with depression in 41% of the patients, while depression without anxiety was observed in 15% of the patients and anxiety without depression was observed in 14% of the patients. The STAI score was found to be significantly correlated with the UPDRS (I, IV) and AS scores, whereas the BDI-II score was found to correlate with the HY stage and the UPDRS (I, III, IV) and AS scores. Both the STAI and BDI-II scores were found to negatively correlate with QOL. A multivariate analysis revealed that depression and anxiety are similarly associated with the PD specific QOL (PDQ-39), while motor severity, as judged by the HY stage and UPDRS III score, is not.
CONCLUSION: These findings indicate that recognizing anxiety and depression in patients with PD is important, since both conditions are commonly observed in patients with PD and are similarly associated with the QOL, independent of motor severity.

Entities:  

Mesh:

Year:  2013        PMID: 23448761     DOI: 10.2169/internalmedicine.52.8617

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  33 in total

1.  Predictors of anxiety in early-stage Parkinson's disease - Results from the first two years of a prospective cohort study.

Authors:  Sonja Rutten; Peter M van der Ven; Daniel Weintraub; Gregory M Pontone; Albert F G Leentjens; Henk W Berendse; Ysbrand D van der Werf; Odile A van den Heuvel
Journal:  Parkinsonism Relat Disord       Date:  2017-07-05       Impact factor: 4.891

2.  Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson's disease and their caregivers.

Authors:  Rosella Ciurleo; Francesco Corallo; Lilla Bonanno; Viviana Lo Buono; Giuseppe Di Lorenzo; Roberta Versaci; Cettina Allone; Rosanna Palmeri; Placido Bramanti; Silvia Marino
Journal:  J Neurol       Date:  2018-06-27       Impact factor: 4.849

3.  The association between clinically relevant anxiety and other non-motor symptoms in Parkinson's disease.

Authors:  Si-Ming Jiang; Yong-Sheng Yuan; Qing Tong; Li Zhang; Qin-Rong Xu; Jian Ding; Ke-Zhong Zhang
Journal:  Neurol Sci       Date:  2015-07-08       Impact factor: 3.307

4.  Neuropsychiatric characteristics of GBA-associated Parkinson disease.

Authors:  Matthew Swan; Nancy Doan; Robert A Ortega; Matthew Barrett; William Nichols; Laurie Ozelius; Jeannie Soto-Valencia; Sarah Boschung; Andres Deik; Harini Sarva; Jose Cabassa; Brooke Johannes; Deborah Raymond; Karen Marder; Nir Giladi; Joan Miravite; William Severt; Rivka Sachdev; Vicki Shanker; Susan Bressman; Rachel Saunders-Pullman
Journal:  J Neurol Sci       Date:  2016-08-30       Impact factor: 3.181

Review 5.  Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson's disease.

Authors:  Atami Sagna; Joseph J Gallo; Gregory M Pontone
Journal:  Parkinsonism Relat Disord       Date:  2014-04-01       Impact factor: 4.891

6.  The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease.

Authors:  Sonja Rutten; Chris Vriend; Ysbrand D van der Werf; Henk W Berendse; Daniel Weintraub; Odile A van den Heuvel
Journal:  Parkinsonism Relat Disord       Date:  2017-02-01       Impact factor: 4.891

Review 7.  Interaction Between Neuropsychiatric Symptoms and Cognitive Performance in Parkinson's Disease: What Do Clinical and Neuroimaging Studies Tell Us?

Authors:  Alexandru Hanganu; Oury Monchi
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-15       Impact factor: 5.081

8.  Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene.

Authors:  Anat Mirelman; Roy N Alcalay; Rachel Saunders-Pullman; Kira Yasinovsky; Avner Thaler; Tanya Gurevich; Helen Mejia-Santana; Deborah Raymond; Mali Gana-Weisz; Anat Bar-Shira; Laurie Ozelius; Lorraine Clark; Avi Orr-Urtreger; Susan Bressman; Karen Marder; Nir Giladi
Journal:  Mov Disord       Date:  2015-03-21       Impact factor: 10.338

9.  Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease.

Authors:  Eleonora Fiorenzato; Angelo Antonini; Valeria Camparini; Luca Weis; Carlo Semenza; Roberta Biundo
Journal:  J Neural Transm (Vienna)       Date:  2019-08-20       Impact factor: 3.575

Review 10.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.